Cosmetic Advisories

FDA Advisory No. 2017-278 || Public Health Warning Against the Use of Counterfeit Cosmetic Products (Batch 5)

FDA Advisory 2017-278 

Public Health Warning Against the Use of Counterfeit Cosmetic Products (Batch 5)

The Food and Drug Administration (FDA) advises the public against the purchase and use of the cosmetic product, NIVEA BABY SOFT-CRÈME WIPES whose particulars/details are provided below:


FDA, in coordination with the Market Authorization Holder (MAH), Beiersdorf Philippines Inc., has verified that the aforementioned cosmetic product is a COUNTERFEIT. According to the MAH, the artwork seen in Figure 1 is the only artwork used by Nivea for Nivea Baby Soft & Cream Wipes. Below is a comparison of the authentic Nivea Baby Soft & Cream Wipes vs. the counterfeit product whose product name, Nivea Baby Soft-Crème Wipes, is slightly different from the real product.

Counterfeit products, not having gone through the required safety assessment and the verification process of the FDA, pose potential health hazards to the consuming public since their safety and purity cannot be guaranteed. The dangers/hazards may come from ingredients that are not allowed to be part of a cosmetic product or from the contamination of heavy metals such as lead and mercury. The use of substandard and possibly adulterated cosmetic products may result to adverse reactions including but not limited to skin irritation, itchiness, anaphylactic shock and organ failure.

In light of the above, the public is advised to be vigilant against buying and using the aforementioned counterfeit cosmetic product. Moreover, the public is also advised to be vigilant against cosmetic products that might not be duly notified with FDA. Always check if a cosmetic product has been notified with FDA before purchasing it by making use of the embedded Search feature of the FDA website accessible at www.fda.gov.ph.

All concerned establishments are warned not to distribute the above-identified violative cosmetic product, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that the product is not sold or made available in their localities or areas of jurisdiction.

To report any suspicious and/or illegal activity involving the said product, the public may contact FDA through its online reporting facility, eReport, at www.fda.gov.ph/ereport, or e-mail us at This email address is being protected from spambots. You need JavaScript enabled to view it., or call the Center for Cosmetics Regulation and Research (CCRR) hotline (02) 857-1979 or (02) 857-1984.

 

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter